Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
ASMB Stock Chart & Stats
$26.90
-$0.45(-2.59%)
At close: 4:00 PM EST
$26.90
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$7.75 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$414.73M
Enterprise Value$211.86M
Total Cash (Recent Filing)$232.56M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 05, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,817,140
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.84
Price to Sales (P/S)3.32
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue5.70
Enterprise Value/Gross Profit31.22
Enterprise Value/Ebitda-5.09
Forecast
1Y Price Target
$43.00Price Target Upside59.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy ResultsPhase 1b data showed helicase‑primase inhibitors achieved very high reductions in HSV-2 viral shedding and lesion rates while maintaining placebo-like safety, supporting a potential best-in-class weekly oral option.
Near-term Pipeline MilestoneABI-5366's planned advancement into Phase 2 in mid-2026 represents a clear near-term development catalyst that could broaden the program's lifecycle and value.
Strategic Collaboration FundingGilead's opt-in includes a $35 million payment, up to $330 million in milestone potential, and a 40% U.S. profit-share that provide meaningful funding and reduce financial risk for HSV program advancement.
Bears Say
Commercial Adoption RiskSlow uptake by prescribers or limited payer support for new antiviral regimens could constrain market penetration and pressure revenue forecasts.
Financing And Dilution RiskFunding multiple clinical programs may require additional capital raises that could dilute existing shareholders if internal resources prove insufficient.
Manufacturing And Regulatory Delay RiskManufacturing challenges or regulatory setbacks could delay trial progress or approvals, extending timelines and increasing development costs.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.75 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $414.73M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Mar 05, 2026 which is in 22 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Nov 10, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.821 by $0.101.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.86.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 15,817,140 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.821. Following the earnings report the stock price went up 3.305%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (59.85% Upside)
$43.00 (59.85% Upside)
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-36.94%
Trailing 12-Months
Asset Growth
-29.95%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$43.00
▲(59.85% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
29.34% Insiders
4.52% Mutual Funds
0.19% Other Institutional Investors
62.75% Public Companies and
Individual Investors